The number of people diagnosed with diabetes in England has exceeded four million for the first time, according to NHS data, representing one of the most significant chronic disease burdens facing the health service and a condition whose management consumes a disproportionately large share of NHS resources relative to almost any other condition category. Type 2 diabetes, which is closely associated with obesity, physical inactivity and ageing, accounts for approximately 90 percent of the total, with the remainder attributable to type 1 and rarer forms.
The steady growth in diabetes prevalence reflects demographic and lifestyle trends that have been building for decades. The ageing of the population automatically increases the number of people who develop the age-related risks associated with type 2 diabetes. The sustained high rates of obesity in the adult population — affecting around a quarter of the UK population at any given time — maintain the primary modifiable risk factor at elevated levels. The combination of these two factors creates a case burden that shows no signs of stabilising, let alone declining.
The NHS Diabetes Prevention Programme, which offers structured lifestyle interventions to people identified as being at high risk of developing type 2 diabetes, has enrolled millions of participants since its launch and has evidence of effectiveness in delaying or preventing the condition in those who complete the programme. However, completion rates are suboptimal and the programme reaches only a fraction of those eligible, limiting its population-level impact.
GLP-1 medications — the same class of drugs driving the obesity treatment expansion — also have significant effects on blood glucose control and have been shown to reduce the risk of cardiovascular complications in people with type 2 diabetes. The NHS is navigating how to integrate these medications into its diabetes management pathway alongside the existing treatment options.
